Date of Degree
Lynn C. Francesconi
Melissa A. Deri
Cathy S. Cutler
Jason S. Lewis
Jennifer A. Shusterman
Inorganic Chemistry | Radiochemistry
Inorganic, Radiochemistry, Radiopharmaceuticals, Radiometals
The use of radiometals in radiopharmaceutical development has drastically increased over the last decade, owed in part to the diverse chemistry and emission characteristics of the radiometals, which allow chemists to create a toolbox of agents to better tailor patient care. Challenges with the use of radiometals include the selection of the metal and the development of optimized chelators to cover the diverse chemistry of the metals which make up the majority of the periodic table. Scandium is the first transition metal and has multiple radioisotopes whose emission characteristics have potential application in medicine. 3,4,3-LI(1,2-HOPO) is a chelator whose denticity, donor atoms, and chelation-pocket size are excellently suited for stabilizing the Sc(III) ion, in addition to a number of other metals. Thus in this thesis, several projects relating to radioscandium and 3,4,3-LI(1,2-HOPO) will be addressed, including the production and purification of medically relevant radionuclides of scandium, the characterization and evaluation of Sc-HOPO and its radiolabeled analogues, the development of a ligand peptide conjugate using 3,4,3-LI(1,2-HOPO), and the characterization of complexes of 3,4,3-LI(1,2-HOPO) with other metals relevant to radiopharmaceuticals.
Phipps, Michael, "The Development of Novel Radioscandium and Hydroxypyridinonate Based Radiopharmaceuticals" (2023). CUNY Academic Works.
This work is embargoed and will be available for download on Tuesday, September 30, 2025
Graduate Center users:
To read this work, log in to your GC ILL account and place a thesis request.
See the GC’s lending policies to learn more.